Relmada Therapeutics, Inc. financial data

Symbol
RLMD on Nasdaq
Industry
Pharmaceutical Preparations
Location
2222 Ponce De Leon Blvd. 3 Rd Floor, Coral Gables, Florida
State of incorporation
Nevada
Fiscal year end
December 31
Former names
CAMP NINE, INC. (to 7/14/2014)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 945 % -14.8%
Return On Equity -93.4 % -6.22%
Return On Assets -91.3 % -9.87%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 30.2 M shares +0.25%
Common Stock, Shares, Outstanding 30.2 M shares +0.25%
Entity Public Float 73 M USD -87%
Common Stock, Value, Issued 30.2 K USD +0.25%
Weighted Average Number of Shares Outstanding, Basic 30.1 M shares +0.11%
Weighted Average Number of Shares Outstanding, Diluted 30.1 M shares +0.11%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 52.3 M USD -49.8%
General and Administrative Expense 46.3 M USD -1.38%
Operating Income (Loss) -98.5 M USD +34.8%
Nonoperating Income (Expense) 4.24 M USD -43.4%
Net Income (Loss) Attributable to Parent -94.3 M USD +34.3%
Earnings Per Share, Basic -3.13 USD/shares +34.4%
Earnings Per Share, Diluted -3.13 USD/shares +17.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.34 M USD -95.4%
Other Assets, Current 256 K USD
Assets, Current 84.4 M USD -37.8%
Other Assets, Noncurrent 43.1 K USD +23.7%
Assets 84.4 M USD -37.7%
Accounts Payable, Current 5.19 M USD +17.3%
Accrued Liabilities, Current 7.17 M USD +26.4%
Liabilities, Current 12.4 M USD +22.4%
Liabilities 12.4 M USD +22.4%
Retained Earnings (Accumulated Deficit) -583 M USD -19.3%
Stockholders' Equity Attributable to Parent 72 M USD -42.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 166 M USD +129%
Liabilities and Equity 84.4 M USD -37.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13 M USD +21%
Net Cash Provided by (Used in) Financing Activities 222 K USD
Net Cash Provided by (Used in) Investing Activities 10.1 M USD -74.9%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 30.2 M shares +0.25%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.5 M USD +4686%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.34 M USD -95.4%
Deferred Tax Assets, Valuation Allowance 110 M USD -5.38%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Preferred Stock, Shares Authorized 200 M shares +5614%
Additional Paid in Capital 655 M USD +6.66%
Share-based Payment Arrangement, Expense 8.3 M USD -26.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%